KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Shares Outstanding (Weighted Average) (2017 - 2025)

Pfizer (PFE) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $5.7 billion as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) changed 0.34% to $5.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 billion through Dec 2025, changed 0.34% year-over-year, with the annual reading at $5.7 billion for FY2025, 0.34% changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $5.7 billion at Pfizer, roughly flat from $5.7 billion in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $5.7 billion in Q3 2025, with the low at $5.6 billion in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $5.6 billion, with a median of $5.6 billion recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 0.86% in 2021, then increased 0.12% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $5.6 billion in 2021, then grew by 0.12% to $5.6 billion in 2022, then increased by 0.62% to $5.6 billion in 2023, then increased by 0.37% to $5.7 billion in 2024, then grew by 0.34% to $5.7 billion in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $5.7 billion, $5.7 billion, and $5.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.